Semaglutide, SL RDT

Semaglutide, SL RDT Description^1-6

Semaglutide, SL RDT is a synthetic glucagon-like peptide-1 receptor agonist (GLP-1 RA) and functions as an incretin mimetic. Incretins are hormones released from the gastrointestinal tract into systemic circulation that assist with glycemic regulation and have also been utilized in weight management. When administered orally, semaglutide has been used for the following indication:

• Treatment of type 2 diabetes mellitus as an adjunct to diet and exercise

Available evidence indicates that oral semaglutide may produce clinically meaningful outcomes for individuals seeking weight reduction. In a 68-week study, oral semaglutide was associated with a 15% decrease in body weight.

References

1. Semaglutide (Ozempic) Prescribing Information – Novo Nordisk https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209637lbl.pdf. Revised December 2017. Accessed May 27, 2025
2. Semaglutide (Wegovy) Prescribing Information Novo Nordisk www.accessdata.fda.gov/drugsatfda_docs/label/2023/215256s007lbl.pdf. Revised July 2023. Accessed June 22, 2025
3. Semaglutide (Rybelsus) Prescribing Information https://www.novo-pi.com/rybelsus.pdf December 2024. Accessed June 22, 2025
4. Clinical Pharmacology semaglutide clinical monograph 2025 https://www.clinicalkey.com/pharmacology/
5. Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol (Lausanne). 2019 Apr 12;10:155.
6. Knop FK, Aroda VR, do Vale RD, Holst-Hansen T, Laursen PN, Rosenstock J, Rubino DM, Garvey WT; OASIS 1 Investigators. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023 Aug 26;402(10403):705-719. https://packageinserts.bms.com/pi/pi_glucophage_xr.pdf